Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Unit-II, API manufacturing facility located at Gaddapotharam, Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, Telangana.
The facility has been classified as Voluntary Action Indicated (VAI) by the USFDA.
Earlier, the USFDA inspected the manufacturing facility from September 7, 2026, to September 15, 2026.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.